Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | MGMT | P16455 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663924 | 1.00 | HDAC1 (0.43) | HDAC1HDAC2HDAC6HDAC4MGMT | |
| SCHEMBL1663801 | 1.00 | HDAC1 (0.43) | HDAC1HDAC2HDAC6HDAC4MGMT | |
| SCHEMBL10510295 | 0.94 | HDAC1 (0.44) | HDAC1HDAC2HDAC6HDAC4MGMT | |
| SCHEMBL5962141 | 0.84 | HSP90AB1 (0.38) | HDAC1HDAC2HDAC6HDAC4HSP90AA1 | |
| SCHEMBL6940477 | 0.84 | HSP90AB1 (0.38) | HDAC1HDAC2HDAC6HDAC4HSP90AA1 | |
| SCHEMBL31187469 | 0.83 | HDAC6 (0.49) | HDAC1HDAC2HDAC6HDAC4HSP90AA1 | |
| SCHEMBL2916968 | 0.83 | HDAC6 (0.49) | HDAC1HDAC2HDAC6HDAC4HSP90AA1 | |
| SCHEMBL1663883 | 0.83 | PNP (0.58) | ALDH1A1CYP3A4HIF1AHPRT1HSD17B10 | |
| SCHEMBL1665922 | 0.83 | PNP (0.58) | ALDH1A1CYP3A4HIF1AHPRT1HSD17B10 | |
| Hydrochloric Acid SCHEMBL5930461 | 0.82 | HDAC6 (0.48) | HDAC1HDAC6HDAC4HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-04-21 | — | — | US | disclosed |
| US-7045525-B1 | Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-0822817-B1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | NOVARTIS INT PHARM LTD (BM) | 2003-07-23 | — | — | EP | disclosed |
| EP-0822817-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996033720-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | HDAC1 2139/4885HDAC2 3261/4885HDAC6 3959/4885 |
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | HDAC1 2139/4885HDAC2 3261/4885HDAC6 3959/4885 |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | TYMP, PNP, HPRT1 | HDAC1 2139/4885HDAC2 3261/4885HDAC6 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.